S
Shanghai Lechun Biotechnology
Single-use bioprocessing solutions for the biopharmaceutical industry
About Shanghai Lechun Biotechnology
Shanghai LePure Biotech Co., Ltd. is a provider of single-use bioprocessing solutions for the biopharmaceutical industry. Founded in 2011 by Chairwoman Qin Sunxing and co-founder and CEO Frank Wang, the company was one of the first domestic providers of single-use consumables and equipment for biopharmaceutical companies in China. LePure Biotech offers a comprehensive product suite that covers the entire biopharmaceutical process, from upstream cell cultivation to downstream separation and purification, and final drug formulation and filling.
The company's offerings include single-use bags, tubing and assemblies, bioreactors, filters, and fluid management equipment. Through strategic acquisitions, LePure has expanded its portfolio to include filtration and purification solutions, as well as cell culture media. In November 2022, the company acquired QuaCell Biotechnology, entering the cell culture media business. This was followed by the acquisition of GeShi Fluid in January 2023, which has over 20 years of experience in filtration and purification technology, significantly strengthening LePure's position in the filtration market.
LePure Biotech operates with a vertically integrated manufacturing model, controlling the process from in-house film extrusion to final product assembly to ensure quality and consistency. The company serves biopharmaceutical clients, including those in monoclonal antibody, vaccine, and cell therapy sectors, and has provided solutions to over 600 biopharmaceutical companies in China, while also exporting to the USA, Singapore, South Korea, and Germany. The firm has received significant investment from world-renowned investors. In January 2023, it closed a Series C financing round co-led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management. These funds are intended to accelerate product innovation and support overseas expansion.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2023 | $28M | $110M | General Atlantic · Goldman Sachs · HM Capital · Honghui Capital | ↗ |
| SERIES BOther financing | Dec 2021 | $0 | — | New Alliance Capital · Hillhouse Capital · Huimei Technology | — |
Growth signals
Latest recorded traffic for Shanghai Lechun Biotechnology is 20 monthly website visits, down 89.5% over the last three months. Shanghai Lechun Biotechnology's team grew 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Lechun Biotechnology in the Songjiang District ecosystem
The Shanghai Lechun Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
New Alliance Capital
Hillhouse Capital
Huimei Technology
Series B and later8 investors entered at this stage
General Atlantic
Goldman Sachs
HM Capital- HCHonghui Capital
- HFHuaying Health Fund
Novo Holdings- CIChina Science and Technology Innovation
- KCKangjun Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Lechun Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Lechun Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








